Prognosis for loss-of-function versus hot-spot variants in RBM20-related cardiomyopathy @ahermidaj https://t.co/rAO5FpJrJq

Systematic analysis of SCN5A variants associated with inherited cardiac diseases https://t.co/lZlF4elf3c

@hrs_journal @ADeliniere @CHUAmiens @amir_zouaghi @RythmologieLyon @EloiMarijon @victor_waldmann @JedraszakG @egandj @GuenanciaC @Gabriel40211637 @SandroNinni @WaintraubX @RodrigueGarcia4 @MartinsRaphae15 @LaredoMikael @BEYLS87 @jshermida

Online on the closing day of the Olympic Games 🏊‍♂️🥋⚽️🏀🏓. Publishing is also a sport, writing requires a long preparation . Three years of work, 362 SCN5A variants reviewed, more than 500 patients phenotyped. See the conclusions below👇! https://t.co/DAyNsb1Ju6

Check out our latest study on right and left atrial strain to identify high-risk NOAF patients in septic shock with bi-atrial dysfunction. @Crit_Care @ahermidaj @pierrehuette @CamilleDaumin

la promotion 2024 des universitaires en Cardiologie. Felicitations à tous ! il nous reste à progresser vers la parité. Nous ne manquons pas de modèles féminins ⁦@heleltchaninoff⁩ ⁦@MartineGilard⁩ @marie-claudeMorice

I'm pleased to share this recently published article, in which we found no benefit from beta blockers in type 3 long QT syndrome https://t.co/cTQHfKxJJf

Our data do not suggest that AKAP9 variants have a causal role in inherited cardiac diseases and indicate that AKAP9 screening is of limited clinical utility

From @ahermidaj+ Ader + team: NEXN Gene in Cardiomyopathies and Sudden Cardiac Deaths: Prevalence, Phenotypic Expression, and Prognosis https://t.co/GZRJD3lCbR @AHAScience #AHAjournals #CardioTwitter #Genetics 📽️@hj_tadros 🎙️@AnwarChahal

Cardiac #SBRT ☢️🎯 as a last-resort strategy for #LVAD patients with intractable VAs ⚡🌩️ Great collaboration with M.Lloyd @KHigginsMD from @EmoryUniversity, @ChuSaintEtienne and @GuenanciaC from @univbourgogne, in @JACCJournals https://t.co/yyGPfnPI7y

Just out @Circ_Gen! Phenotypic Characterization of Timothy Syndrome Caused by the CACNA1C p.Gly402Ser Variant https://t.co/COBLsACoxN @RythmologieLyon @ahermidaj @BabkenAsatryan @HCL_research @FCardiogen @ERNGuardHeart

@jshermida @CHUAmiens What is your strategy? @SandroNinni @MartinsRaphae15 @pmlallemand @LaredoMikael @WaintraubX @RodrigueGarcia4

Ablation for PeAF ? Strategy @jshermida @CHUAmiens First step = cryo-PVI. Fast, safe. SR at 2 years = 51%. https://t.co/0z6WGYSVuZ Second step for persistent ATa recurrence = linear lesions (CTI, roof, MI). SR at 3 years = 69%. https://t.co/5d0gdbS7N1

The accuracy of automated AF diagnoses varies between smart devices models: 👉Bordeaux Study: https://t.co/osIIAYGZZU 👉Basel Study: https://t.co/CQf794clA1 You can also watch my presentation at #stimudef @rythmo_sfc with the help of @WaintraubX https://t.co/mn2I5Tw8bx

Two-year prognosis of ACS 🫀 during the 1st national lockdown 👉↘️ 30% ACS admission @CHUAmiens 👉no difference in MACE/death at the acute phase 👉no difference in MACE/death at 2 years @BEYLS87 @yohann_bohbot @osamaabouarab @SFCardio @ACVD 🇫🇷 https://t.co/93MQN2xyFV

Check out the results of our last paper, the 🥳PARTY-PVI study🥳, analyzing the impact of various ablation strategies in patients with recurrent AF despite 4 PVs isolated, published in @CirculationEP 39 🇫🇷 centers, 367 patients @KarimBenali42 et al https://t.co/MZ63eDcGAH #Epeeps

Uso de ranolazina en paciente con síndrome de Timothy tipo 2 #REC #Cardiotwitter @ahermidaj https://t.co/BU6rBx9SNF

1/ Endo-epi ablation in a patient with recent inferior MI and ECMO for drug refractory VT. Done with @ahermidaj and the great BW mapper Romain Sauvé #EPeeps #AblateVT

First-line cryoablation appears not only to be superior to drug therapy in preventing the recurrence of symptomatic episodes and decreasing AF burden but also in improving quality of life in symptomatic paroxysmal AF.

Air bubble trapped in the left atrial appendage